In 2017, the European biotech sector witnessed a volume increase in IPOs and follow-on financings. This says...
Up To Date
Latest News
Swiss oncolytic virus and vaccine specialist NousCom has closed a €42m Series B financing round led by new...
Researchers at Belgian UCB SA have clinically demonstrated that an antibody targeting a normal cellular...
Following the death of a patient with blastic plasmacytoid dendritic cell neoplasm (BPDCN), the FDA put a hold...
Dutch venture capital company BioGeneration Ventures (BGV) has closed its third fund, BGV III, at €82m...
Belgian nanobody producer Ablynx closes an initial public offering of American Depositary Shares at Nasdaq...
Share
